(St. Louis; March 10, 2015)– Biomedical Systems, a premier global provider of centralized diagnostic services, launches its second generation clinical outcome assessment software offering three easy-to-use platforms to collect patient data. This new electronic patient recorded outcome (ePRO) technology improves patient and investigator user experience, improves patient compliance and expedites study setup by simplifying site tasks and reducing errors.
Biomedical Systems’ electronic clinical outcome assessment (eCOA) technology is used for clinical trials in more than 40 countries for multiple therapeutic areas including respiratory, gastrointestinal, dermatology, oncology and women’s health. Biomedical Systems is the only company providing eCOA technology along with cardiac safety, pulmonary function and imaging centralized diagnostic services.
“The eCOA market is growing fast, and launching this technology enhances our ability to offer centralized diagnostic services,” said Tim Barrett, chief executive officer at Biomedical Systems. “In 40 years, Biomedical Systems has built a premier global presence based on centralized diagnostic services and logistics excellence. Our eCOA solutions will extend that prompt, reliable global service we’re known for to provide more reliable data while collecting data for primary and secondary endpoints.”
Biomedical Systems’ eCOA technology offers the flexibility, reliability and robustness of the Android operating system. QR code technology is used to reduce investigators’ burden, improve security and, more importantly, ease the data capture process. With this platform, Biomedical Systems focused on patients’ ease of use by providing new features that improve compliance and worldwide reliable data transmission using the latest telecommunication technologies. In addition, Biomedical Systems relies on a strong and proactive project management team that is key to successful eCOA trials.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.